P2, Although the data may show that Tamoxifen may prevent some cases of breast cancer, it's far from an ideal drug:
"Leslie Ford, the National Cancer Institute official overseeing the trial, predicted four years ago that if 16,000 women were recruited, tamoxifen would be expected to prevent 120 to 125 breast cancer cases, while producing 58 to 80 new cases of uterine cancer - which is far easier to detect early and cure than breast cancer."
Tamoxifen's competition in the SERM area comes from Evista, Drolixifene, Idoxifene, CP-366,156, and TSE424. Some of these compounds are structurally similar ( I believe that Droloxifene is a derivative of Tamoxifen) to Tamoxifen which acts through the estrogen receptor.
Targretin is a rexinoid that acts through RXRs. Although it has been shown to be superior to Tamoxifen in rat breast cancer models (the superiority is stronger is for treatment that prevention), it has been shown to synergize with Tamoxifen in both areas (treatment as well as prevention). |
